Meeting Report EuroG20 Meeting on Cancer-Associated Thrombosis (CAT) Bergamo, Italy 7 April 2016

References

• Portillo J, de la Rocha IV, Font L, Braester A, Madridano O, Peromingo JA, Apollonio A, Pagán B, Bascuñana J, Monreal M, et al. Venous thromboembolism in patients with glioblastoma multiforme: Findings of the RIETE registry. Thromb Res. 2015;136:1199–1203. doi:10.1016/j.thromres.2015.10.043. PMID:26548619.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33:654–656. doi:10.1200/JCO.2014.59.7351. PMID:25605844.
   PubMed Web of Science ®Google Scholar
• Donato J, Campigotto F, Uhlmann EJ, Coletti E, Neuberg D, Weber GM, Zwicker JI Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study. Blood. 2015;126:494–499. doi:10.1182/blood-2015-02-626788. PMID:25987658.
   PubMed Web of Science ®Google Scholar
• Rojas-Hernandez CM, Oo TH, Garcia-Perdomo AH. Risk of intracranial hemorrhage associated with therapeutic anticoagulation for venous thromboembolism in cancer patients: a systematic review and meta-analysis. J Thromb Thrombolysis 2017;43:233–240. doi:10.1007/s11239-016-1434-4. PMID:27704333.
   PubMed Web of Science ®Google Scholar
• Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146–153. doi:10.1056/NEJMoa025313. PMID:12853587.
   PubMed Web of Science ®Google Scholar
• Lee AY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, Khorana AA, CATCH Investigators. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. JAMA. 2015;314:677–686. doi:10.1001/jama.2015.9243. PMID:26284719.
   PubMed Web of Science ®Google Scholar
• Carrier M, Le Gal G, Cho R, Tierney S, Rodger M, Lee AY. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost. 2009;7:760–765. doi:10.1111/j.1538-7836.2009.03326.x. PMID:19245418.
   PubMed Web of Science ®Google Scholar
• Schulman S, Zondag M, Linkins L, Pasca S, Cheung YW, de Sancho M, Gallus A, Lecumberri R, Molnar S, Ageno W, et al. Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis. J Thromb Haemost. 2015;13:1010–1018. doi:10.1111/jth.12955. PMID:25851122.
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149:315–352. doi:10.1016/j.chest.2015.11.026. PMID:26867832.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Carrier M, Garcia DA, Lee AY. Guidance for the prevention and treatment of cancer-associated venous thromboembolism. J Thromb Thrombolysis. 2016;41:81–91. doi:10.1007/s11239-015-1313-4. PMID:26780740.
   PubMed Web of Science ®Google Scholar
• Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost. 2013;11:56–70. doi:10.1111/jth.12070. PMID:23217107.
   PubMed Web of Science ®Google Scholar
• Carrier M, Lazo-Langner A, Shivakumar S, Tagalakis V, Gross PL, Blais N, Butts CA, Crowther M. Clinical challenges in patients with cancer-associated thrombosis: Canadian expert consensus recommendations. Curr Oncol. 2015;22:49–59. doi:10.3747/co.22.2392. PMID:25684988.
   PubMed Web of Science ®Google Scholar
• Raphael D, Rukholm E, Brown I, Hill-Bailey P, Donato E The Quality of Life Profile–Adolescent Version: background, description, and initial validation. J Adolesc Health. 1996;19:366–375. doi:10.1016/S1054-139X(96)00080-8. PMID:8934298.
   PubMed Web of Science ®Google Scholar
• Seaman S, Nelson A, Noble S. Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study. Patient Prefer Adherence. 2014;8:453–461. PMID:24748774.
   PubMed Web of Science ®Google Scholar
• Noble S, Prout H, Nelson A Patients' Experiences of LIving with CANcer-associated thrombosis: the PELICAN study. Patient Prefer Adherence. 2015;9:337–345. doi:10.2147/PPA.S79373. PMID:25750522.
   PubMed Web of Science ®Google Scholar
• Noble S, Matzdorff A, Maraveyas A, Holm MV, Pisa G Assessing patients' anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology. Haematologica. 2015;100:1486–1492. doi:10.3324/haematol.2015.127126. PMID:26294737.
   PubMed Web of Science ®Google Scholar
• Louzada ML, Majeed H, Wells PS Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials. Thromb Res. 2009;123:837–844. doi:10.1016/j.thromres.2008.09.002. PMID:18977517.
   PubMed Web of Science ®Google Scholar
• Posch F, Konigsbrugge O, Zielinski C, Pabinger I, Ay C. Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res. 2015;136:582–589. doi:10.1016/j.thromres.2015.07.011. PMID:26210891.
   PubMed Web of Science ®Google Scholar
• Scotte F, Rey JB, Launay-Vacher V. Thrombosis, cancer and renal insufficiency: low molecular weight heparin at the crossroads. Support Care Cancer. 2012;20:3033–3042. doi:10.1007/s00520-012-1590-9. PMID:22960941.
   PubMed Web of Science ®Google Scholar
• Janus N, Launay-Vacher V, Byloos E, Machiels JP, Duck L, Kerger J, Wynendaele W, Canon JL, Lybaert W, Nortier J, et al. Cancer and renal insufficiency results of the BIRMA study. Br J Cancer. 2010;103:1815–1821. doi:10.1038/sj.bjc.6605979. PMID:21063408.
   PubMed Web of Science ®Google Scholar
• Mahe I, Sterpu R, Bertoletti L, et al. Long-term anticoagulant therapy of patients with venous thromboembolism. What are the practices? PLoS One. 2015;10:e0128741. doi:10.1371/journal.pone.0128741. PMID:26076483.
   PubMed Web of Science ®Google Scholar
• Trujillo-Santos J, Nieto JA, Tiberio G, et al. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008;100:435–439. PMID:18766259.
   PubMed Web of Science ®Google Scholar
• Kooiman J, den Exter PL, Cannegieter SC, le Cessie S, del Toro J, Sahuquillo JC, Pedrajas JM, Huisman MV Impact of chronic kidney disease on the risk of clinical outcomes in patients with cancer-associated venous thromboembolism during anticoagulant treatment. J Thromb Haemost. 2013;11:1968–1976. doi:10.1111/jth.12411. PMID:24112123.
   PubMed Web of Science ®Google Scholar
• Elalamy I, Canon JL, Bols A, Lybaert W, Duck L, et al. Thrombo-embolic events in cancer patients with impaired renal function. J Blood Disord Transfus. 2014;5:202–208..
   Google Scholar
• Trujillo-Santos J, Schellong S, Falga C, et al. Low-molecular-weight or unfractionated heparin in venous thromboembolism: The influence of renal function. Am J Med. 2013;126:425–434 doi:10.1016/j.amjmed.2012.09.021. PMID:23499331.
   PubMed Web of Science ®Google Scholar
• Akl EA, Vasireddi SR, Gunukula S, et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev. 2011;2:1–63: CD006649.
   Google Scholar
• Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484–3488. doi:10.1182/blood-2002-01-0108. PMID:12393647.
   PubMed Web of Science ®Google Scholar
• Bauersachs RM Managing venous thromboembolism with novel oral anticoagulants in the elderly and other high-risk patient groups. Eur J Intern Med. 2014;25:600–606. doi:10.1016/j.ejim.2014.05.017. PMID:24972957.
   PubMed Web of Science ®Google Scholar
• Wei MY, Ward SM. The anti-factor xa range for low molecular weight heparin thromboprophylaxis. Hematol Rep. 2015;7:5844. doi:10.4081/hr.2015.5844. PMID:26733269.
   PubMed Web of Science ®Google Scholar
• Freeman A, Horner T, Pendleton RC, Rondina MT Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity. Am J Hematol. 2012;87:740–743. doi:10.1002/ajh.23228. PMID:22565589.
   PubMed Web of Science ®Google Scholar
• Yentz S, Onwuemene OA, Stein BL, Cull EH, McMahon B. Clinical use of anti-Xa monitoring in malignancy-associated thrombosis. Thrombosis. 2015;2015:126975. doi:10.1155/2015/126975. PMID:26543644.
   PubMedGoogle Scholar
• Shapiro NL, Kominiarek MA, Nutescu EA, Chevalier AB, Hibbard JU. Dosing and monitoring of low-molecular-weight heparin in high-risk pregnancy: single-center experience. Pharmacotherapy. 2011;31:678–685. doi:10.1592/phco.31.7.678. PMID:21923455.
   PubMed Web of Science ®Google Scholar
• Bauman ME, Belletrutti MJ, Bajzar L, Black KL, Kuhle S, Bauman ML, Patricia Massicotte M. Evaluation of enoxaparin dosing requirements in infants and children. Better dosing to achieve therapeutic levels. Thromb Haemost. 2009;101:86–92. PMID:19132193.
   PubMed Web of Science ®Google Scholar
• Lim SY, Jeon K, Kim HJ, Kim SM, Song J, Ha JM, Um SW, Koh WJ, Chung MP, Kim H, et al. Antifactor Xa levels in critically ill Korean patients receiving enoxaparin for thromboprophylaxis: a prospective observational study. J Korean Med Sci. 2013;28:466–471. doi:10.3346/jkms.2013.28.3.466. PMID:23487580.
   PubMed Web of Science ®Google Scholar
• Mayr AJ, Dunser M, Jochberger S, Fries D, Klingler A, Joannidis M, Hasibeder W, Schobersberger W Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin. Thromb Res. 2002;105:201–204. doi:10.1016/S0049-3848(02)00028-2. PMID:11927124.
   PubMed Web of Science ®Google Scholar
• Smythe MA, Priziola J, Dobesh PP, Wirth D, Cuker A, Wittkowsky AK. Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. J Thromb Thrombolysis. 2016;41:165–86. doi:10.1007/s11239-015-1315-2. PMID:26780745.
   PubMed Web of Science ®Google Scholar
• Ludwig H, Beksac M, Blade J, Boccadoro M, Cavenagh J, Cavo M, Dimopoulos M, Drach J, Einsele H, Facon T, et al. Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist. 2010;15:6–25. doi:10.1634/theoncologist.2009-0203. PMID:20086168.
   PubMed Web of Science ®Google Scholar
• Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293:715–722. doi:10.1001/jama.293.6.715. PMID:15701913.
   PubMed Web of Science ®Google Scholar
• Srkalovic G, Cameron MG, Rybicki L, Deitcher SR, Kattke-Marchant K, Hussein, MA Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer. 2004;101:558–566. doi:10.1002/cncr.20405. PMID:15274069.
   PubMed Web of Science ®Google Scholar
• Falanga A, Marchetti M Venous thromboembolism in the hematologic malignancies. J Clin Oncol. 2009;27:4848–4857. doi:10.1200/JCO.2009.22.8197. PMID:19752334.
   PubMed Web of Science ®Google Scholar
• Zangari M, Fink L, Zhan F, Tricot G. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens. Clin Lymphoma Myeloma Leuk. 2011;11:228–236. doi:10.1016/j.clml.2011.03.006. PMID:21575928.
   PubMed Web of Science ®Google Scholar
• San Miguel J, Weisel K, Moreau P, M L, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:1055–1066. doi:10.1016/S1470-2045(13)70380-2. PMID:24007748.
   PubMed Web of Science ®Google Scholar
• Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R, Badros AZ, Jagannath S, McCulloch L, Rajangam K, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013;98:1753–1761. doi:10.3324/haematol.2013.089334. PMID:23935022.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142–152. doi:10.1056/NEJMoa1411321. PMID:25482145.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, Rossi D, Gentilini F, Crippa C, Galli M, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol. 2011;29:986–993. doi:10.1200/JCO.2010.31.6844. PMID:21282540.
   PubMed Web of Science ®Google Scholar
• Larocca A, Cavallo F, Bringhen S, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood. 2012;119:933–939, quiz 1093. doi:10.1182/blood-2011-03-344333. PMID:21835953.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22:414–423. doi:10.1038/sj.leu.2405062. PMID:18094721.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25:5490–5505. doi:10.1200/JCO.2007.14.1283. PMID:17968019.
   PubMed Web of Science ®Google Scholar
• Larsen TB, Nielsen PB, Skjoth F, Rasmussen LH, Lip GY Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes. PLoS One. 2014;9:e114445. doi:10.1371/journal.pone.0114445. PMID:25479007.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, Gallus AS, Lee TC, Pak R, Raskob GE, Weitz JI, Yamabe T Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost. 2015;13:2187–2191. doi:10.1111/jth.13153. PMID:26407753.
   PubMed Web of Science ®Google Scholar
• Raskob G, Buller H, Prins M, Segers A, Shi M, Schwocho L, van Kranen R, Mercuri M, Hokusai-VTE Investigators. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study–methodological implications for clinical trials. J Thromb Haemost. 2013;11:1287–1294. doi:10.1111/jth.12230. PMID:23574579.
   PubMed Web of Science ®Google Scholar
• van Es N, Di Nisio M, Bleker SM, Segers A, Mercuri MF, Schwocho L, Kakkar A, Weitz JI, Beyer-Westendorf J, Boda Z, et al. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. Thromb Haemost. 2015;114:1268–1276. doi:10.1160/TH15-06-0452. PMID:26271200.
   PubMed Web of Science ®Google Scholar
• Gasic GJ, Gasic TB, Stewart CC Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci U S A. 1968;61:46–52. doi:10.1073/pnas.61.1.46. PMID:5246932.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Borsig L, Varki NM, Varki A P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci U S A. 1998;95:9325–9330. doi:10.1073/pnas.95.16.9325. PMID:9689079.
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, Lee R, Belch JF, Wilson M, Mehta Z, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379:1602–1612. doi:10.1016/S0140-6736(11)61720-0. PMID:22440946.
   PubMed Web of Science ®Google Scholar
• Vad NM, Kudugunti SK, Wang H, Bhat GJ, Moridani MY Efficacy of acetylsalicylic acid (aspirin) in skin B16-F0 melanoma tumor-bearing C57BL/6 mice. Tumour Biol. 2014;35:4967–4976. doi:10.1007/s13277-014-1654-1. PMID:24492939.
   PubMedGoogle Scholar
• Ageno W, Riva N, Schulman S, Bang SM, Sartori MT, Grandone E, Beyer-Westendorf J, Barillari G, Di Minno MN, Dentali F, et al. Antithrombotic treatment of splanchnic vein thrombosis: results of an international registry. Semin Thromb Hemost. 2014;40:99–105. PMID:24381147.
   PubMed Web of Science ®Google Scholar
• Rajani R, Bjornsson E, Bergquist A, et al. The epidemiology and clinical features of portal vein thrombosis: a multicentre study. Aliment Pharmacol Ther. 2010;32:1154–1162. doi:10.1111/j.1365-2036.2010.04454.x. PMID:21039677.
   PubMed Web of Science ®Google Scholar
• Sogaard KK, Farkas DK, Pedersen L, Sorensen HT Splanchnic venous thrombosis is a marker of cancer and a prognostic factor for cancer survival. Blood. 2015;126:957–963. doi:10.1182/blood-2015-03-631119. PMID:26089394.
   PubMed Web of Science ®Google Scholar
• Dentali F, Squizzato A, Brivio L, Appio L, Campiotti L, Crowther M, Grandi AM, Ageno W JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood. 2009;113:5617–5623. doi:10.1182/blood-2008-12-196014. PMID:19273837.
   PubMed Web of Science ®Google Scholar
• Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood. 2012;120:4921–4928. doi:10.1182/blood-2011-09-376517. PMID:23043069.
   PubMed Web of Science ®Google Scholar
• DeLeve LD, Valla DC, Garcia-Tsao G. American Association for the Study Liver D. Vascular disorders of the liver. Hepatology. 2009;49:1729–1764. doi:10.1002/hep.22772. PMID:19399912.
   PubMed Web of Science ®Google Scholar
• Ageno W, Riva N, Schulman S, Beyer-Westendorf J, Bang SM, Senzolo M, Grandone E, Pasca S, Di Minno MN, Duce R, et al. Long-term clinical outcomes of splanchnic vein thrombosis: Results of an International Registry. JAMA Intern Med. 2015;175:1474–1480. doi:10.1001/jamainternmed.2015.3184. PMID:26168152.
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e419S−494S. doi:10.1378/chest.11-2301. PMID:22315268.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902–4907. doi:10.1182/blood-2007-10-116327. PMID:18216292.
   PubMed Web of Science ®Google Scholar
• Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, Quehenberger P, Zielinski C, Pabinger I. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116:5377–5382. doi:10.1182/blood-2010-02-270116. PMID:20829374.
   PubMed Web of Science ®Google Scholar
• Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366:601–609. doi:10.1056/NEJMoa1108898. PMID:22335737.
   PubMed Web of Science ®Google Scholar
• Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009;10:943–949. doi:10.1016/S1470-2045(09)70232-3. PMID:19726226.
   PubMed Web of Science ®Google Scholar
• van Es N, Di Nisio M, Cesarman G, Kleinjan A, Otten H-M, Mahé I, Wilts IT, Twint DC, Porreca E, Arrieta O, et al. Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica. 2017;102:1494–1501. doi:10.3324/haematol.2017.169060. PMID:28550192.
   PubMed Web of Science ®Google Scholar
• Menapace LA, Khorana AA. The role of thromboprophylaxis in cancer patients: Emerging data. Current opinion in hematology. 2010;17:450–456. doi:10.1097/MOH.0b013e32833c0760. PMID:20601873.
   PubMed Web of Science ®Google Scholar
• Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, Niedergethmann M, Zülke C, Fahlke J, Arning MB, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. Jama. 2013;310:1473–1481. doi:10.1001/jama.2013.279201. PMID:24104372.
   PubMed Web of Science ®Google Scholar